‘Painful’ Few Years In US For Glenmark But Rebound In Sight
API Business Up As Customers Look Beyond China
With price erosion seen ‘hitting the bottom’ in the US, Glenmark expects to make a strong comeback after some tough years in that market. Much will depend on product flow, including injectables, from the new Monroe site, with investors also keeping an eye on regulatory traction for rhinitis therapy Ryaltris.
